Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial

Guillermo Garcia-Manero, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Veronika Pozharskaya, Karen L. Keeperman, Yinzhi Lai, Barkha Aggarwal, Dimana Miteva, David Valcárcel Ferreiras, Pierre Fenaux, Jake Shortt, Matteo Giovanni Della Porta, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 350.

https://doi.org/10.1182/blood-2024-194240

Published: 2024

Journal Articles

Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial

Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, Guillermo Garcia-Manero, Dimana Miteva, Aylin Yucel, Veronika Pozharskaya, Shelonitda Rose, Yinzhi Lai, Ana Carolina Giuseppi, David Valcárcel Ferreiras, Pierre Fenaux, Jake Shortt, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2024-194239

Published: 2024

Journal Articles

Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial

Guillermo Garcia-Manero, Matteo Giovanni Della Porta, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Pierre Fenaux, David Valcárcel, Jake Shortt, Mrudula B. Glassberg, Aylin Yucel, Yinzhi Lai, Dimana Miteva, Shelonitda Rose, Ahmed Hnoosh, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2024-198304

Published: 2024

Journal Articles

Clinical Parameters, Anemia, and Spleen Response in Patients with MF-Related Anemia Treated with Luspatercept: Efficacy Sub-Analysis from the ACE-536-MF-001 Study

Aaron T. Gerds, Claire N Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Rami S. Komrokji, Prithviraj Bose, Fabian Sanabria, Niloufar Marsousi, Yinzhi Lai, Francesco Passamonti

Blood (2023) 142 (Supplement 1): 4565.

https://doi.org/10.1182/blood-2023-178536

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study

Maria Domenica Cappellini, Ali T Taher, Vip Viprakasit, Pencho Georgiev, Kevin H.M. Kuo, Natalia Holot, Valérie Vilmont, Loyse Felber Medlin, Wen-Ling Kuo, Yinzhi Lai, Luciana Moro Bueno, Sujit Sheth

Blood (2023) 142 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2023-174089

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Kevin H.M. Kuo, Pranee Sutcharitchan, Ping Chong Bee, Lee Ping Chew, Soo Min Lim, Ai Sim Goh, Sadanand Vodala, Wen-Ling Kuo, Yinzhi Lai, Loyse Felber Medlin, Martina Perin, Luciana Moro Bueno, Thomas D Coates, Vip Viprakasit

Blood (2023) 142 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2023-174082

Published: 2023

Journal Articles

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Valeria Santini, Rami S. Komrokji, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Karen L. Keeperman, Shelonitda Rose, Ana Carolina Giuseppi, Valerie Vilmont, Yinzhi Lai, Dimana Miteva, Barkha Aggarwal, Uwe Platzbecker, Pierre Fenaux, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 915.

https://doi.org/10.1182/blood-2023-178546

Published: 2023

Journal Articles

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Farhad Ravandi, Pau Montesinos, Michael Pfeilstöcker, Cristina Papayannidis, Hervé Dombret, Yinzhi Lai, Erica Petrlik, Thomas Prebet, Hartmut Döhner

Blood (2022) 140 (Supplement 1): 3277–3279.

https://doi.org/10.1182/blood-2022-159045

Published: 2022

NARROW

Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial

Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial

Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial

Clinical Parameters, Anemia, and Spleen Response in Patients with MF-Related Anemia Treated with Luspatercept: Efficacy Sub-Analysis from the ACE-536-MF-001 Study

Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only